{
    "clinical_study": {
        "@rank": "124540", 
        "arm_group": [
            {
                "arm_group_label": "ALX-0061 low dose i.v.", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ALX-0061 high dose i.v.", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ALX-0061 low dose s.c.", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ALX-0061 middle dose s.c.", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ALX-0061 high dose s.c.", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The overall aims of the study are:\n\n        -  To assess the bioavailability of single doses of ALX-0061, administered s.c. at three\n           dose levels, using 2 corresponding single i.v. dose levels as reference.\n\n        -  To provide additional information on pharmacokinetics and pharmacodynamics of ALX-0061.\n\n        -  To further determine the safety and tolerability of ALX-0061.\n\n        -  To further evaluate the systemic (serum) immunogenicity of ALX-0061."
        }, 
        "brief_title": "ALX-0061 Phase I Bioavailability Study in Healthy Volunteers", 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          1. Healthy volunteers.\n\n          2. Gender: male or female.\n\n          3. Age 18 to 55 years.\n\n          4. Body mass index (BMI): 18.0 \u2265 BMI < 30.0 kg/m2.\n\n        Key Exclusion Criteria:\n\n          1. Any active inflammatory condition, or autoimmune disorder such as lupus\n             erythematosus, multiple sclerosis or rheumatoid arthritis (RA).\n\n          2. Any current or recent (within 4 weeks prior to dose) signs or symptoms of infection\n             that requires parenteral antibiotic administration.\n\n          3. Symptomatic infection, or suspicion thereof in the last 1 week prior to dosing."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101073", 
            "org_study_id": "ALX0061-C102", 
            "secondary_id": "2013-005493-21"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ALX-0061 low dose i.v.", 
                    "ALX-0061 high dose i.v."
                ], 
                "description": "single dose, intravenous", 
                "intervention_name": "ALX-0061", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "ALX-0061 low dose s.c.", 
                    "ALX-0061 middle dose s.c.", 
                    "ALX-0061 high dose s.c."
                ], 
                "description": "single dose, subcutaneous", 
                "intervention_name": "ALX-0061", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zuidlaren", 
                    "country": "Netherlands", 
                    "zip": "9470"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase I, Open-Label Study Evaluating the Bioavailability of ALX-0061 After Subcutaneous and Intravenous Administration in Healthy Volunteers.", 
        "overall_contact": {
            "email": "clinicaltrials@ablynx.com", 
            "last_name": "Ablynx NV Belgium", 
            "phone": "3292620000"
        }, 
        "overall_official": {
            "affiliation": "Ablynx NV", 
            "last_name": "Steven De Bruyn, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pharmacokinetics: serum concentration of ALX-0061 after single subcutaneous (s.c.) and single intravenous (i.v.) doses of ALX-0061 in healthy volunteers", 
            "safety_issue": "No", 
            "time_frame": "Day 1 to Day 32 +/- 2 days after dosing for low dose treatment arms, Day 1 to Day 46 +/-2 days after dosing for middle dose treatment arm, Day 1 to Day 53 +/- 2 days after dosing for high dose treatment arms"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101073"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacodynamics: concentration in plasma of total soluble Interleukin-6 receptor (sIL-6R) and in serum of IL-6", 
                "safety_issue": "No", 
                "time_frame": "During screening untill final visit (i.e. 60 +/- 2 days after dosing for the low dose and middle dose treatment arms and 83 +/- 2 days after dosing for the high dose treatment arms)"
            }, 
            {
                "description": "Adverse events and concomitant medication\nClinical laboratory\nVital signs\n12-lead ECG\nPhysical examination\nLocal reactions", 
                "measure": "Safety and tolerability: safety markers", 
                "safety_issue": "Yes", 
                "time_frame": "From signing of informed consent until final visit (i.e. 60 +/- 2 days for the low dose and middle dose treatment arms and 83 +/- 2 days for the high dose treatment arms"
            }, 
            {
                "measure": "Immunogenicity: concentration of Anti-Drug Antibodies (ADA) in serum", 
                "safety_issue": "No", 
                "time_frame": "From screening until final visit (i.e. 60+/- 2 days after dosing for the low dose and middle dose treatment arms and 83 +/- 2 days after dosing for the high dose treatment arms"
            }
        ], 
        "source": "Ablynx", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ablynx", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}